EA033956B1 - Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7- диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты - Google Patents

Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7- диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты Download PDF

Info

Publication number
EA033956B1
EA033956B1 EA201791592A EA201791592A EA033956B1 EA 033956 B1 EA033956 B1 EA 033956B1 EA 201791592 A EA201791592 A EA 201791592A EA 201791592 A EA201791592 A EA 201791592A EA 033956 B1 EA033956 B1 EA 033956B1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline form
prostate cancer
methylbenzamide
oct
cyano
Prior art date
Application number
EA201791592A
Other languages
English (en)
Russian (ru)
Other versions
EA201791592A1 (ru
Inventor
Николас Д. Смит
Марк Р. Херберт
Оуатек Оуерфелли
Анна Дилхас
Original Assignee
Арагон Фармасьютикалз, Инк.
Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA033956(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Арагон Фармасьютикалз, Инк., Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч filed Critical Арагон Фармасьютикалз, Инк.
Publication of EA201791592A1 publication Critical patent/EA201791592A1/ru
Publication of EA033956B1 publication Critical patent/EA033956B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201791592A 2012-06-07 2013-06-04 Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7- диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты EA033956B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
US61/656,888 2012-06-07

Publications (2)

Publication Number Publication Date
EA201791592A1 EA201791592A1 (ru) 2018-01-31
EA033956B1 true EA033956B1 (ru) 2019-12-13

Family

ID=49712550

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201791592A EA033956B1 (ru) 2012-06-07 2013-06-04 Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7- диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты
EA201992010A EA201992010A1 (ru) 2012-06-07 2013-06-04 Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7-диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты
EA201492272A EA028791B1 (ru) 2012-06-07 2013-06-04 Кристаллическая форма модулятора андрогенных рецепторов

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201992010A EA201992010A1 (ru) 2012-06-07 2013-06-04 Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7-диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты
EA201492272A EA028791B1 (ru) 2012-06-07 2013-06-04 Кристаллическая форма модулятора андрогенных рецепторов

Country Status (45)

Country Link
US (9) US9481663B2 (enExample)
EP (4) EP3348553B1 (enExample)
JP (3) JP6182209B2 (enExample)
KR (2) KR102062024B1 (enExample)
CN (3) CN113135892A (enExample)
AU (3) AU2013271751B2 (enExample)
BR (1) BR112014030678A2 (enExample)
CA (4) CA2875767C (enExample)
CL (1) CL2014003331A1 (enExample)
CO (1) CO7240407A2 (enExample)
CR (2) CR20190331A (enExample)
CY (4) CY1120393T1 (enExample)
DK (3) DK2858985T3 (enExample)
EA (3) EA033956B1 (enExample)
EC (1) ECSP14030098A (enExample)
ES (3) ES2809738T3 (enExample)
FR (1) FR21C1050I2 (enExample)
GT (1) GT201400283A (enExample)
HK (2) HK1210175A1 (enExample)
HR (3) HRP20180902T1 (enExample)
HU (4) HUE038082T2 (enExample)
IL (5) IL267608B2 (enExample)
IN (1) IN2014DN10084A (enExample)
LT (4) LT3348553T (enExample)
LU (1) LUC00236I2 (enExample)
ME (2) ME03081B (enExample)
MX (1) MX356754B (enExample)
MY (1) MY187500A (enExample)
NI (1) NI201400142A (enExample)
NL (1) NL301144I2 (enExample)
NO (1) NO2021046I1 (enExample)
NZ (2) NZ717683A (enExample)
PE (3) PE20150631A1 (enExample)
PH (2) PH12014502714A1 (enExample)
PL (3) PL3533792T3 (enExample)
PT (3) PT3348553T (enExample)
RS (3) RS60617B1 (enExample)
SG (3) SG11201408140QA (enExample)
SI (3) SI3348553T1 (enExample)
SM (3) SMT201800311T1 (enExample)
TR (1) TR201808939T4 (enExample)
TW (1) TWI532732B (enExample)
UA (2) UA115665C2 (enExample)
WO (1) WO2013184681A1 (enExample)
ZA (1) ZA201500076B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CN104169266A (zh) 2011-12-16 2014-11-26 奥乐玛药物股份有限公司 新的苯并吡喃化合物、其组合物和用途
CN113135892A (zh) 2012-06-07 2021-07-20 阿拉贡药品公司 雄激素受体调节剂的晶形
EA033374B9 (ru) 2012-09-11 2019-12-18 Медивейшн Простейт Терапьютикс Ллк Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2016029776A1 (en) * 2014-08-26 2016-03-03 Astar Biotech Llc Protein kinase inhibitors
CN106999430A (zh) 2014-12-05 2017-08-01 阿拉贡药品公司 抗癌组合物
RS66323B1 (sr) 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
MA41111B1 (fr) 2014-12-05 2021-09-30 Aragon Pharmaceuticals Inc Compositions anticancéreuses
WO2016100905A1 (en) 2014-12-19 2016-06-23 Lutron Electronics Co., Inc. Multi-channel lighting fixture having multiple light-emitting diode drivers
SG11201809680QA (en) 2016-06-03 2018-11-29 Aragon Pharmaceuticals Inc Anticancer compositions
ES2952770T3 (es) 2016-12-13 2023-11-06 Watson Lab Inc Formas de estado sólido de apalutamida
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
WO2019242439A1 (zh) * 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
US20220281836A1 (en) * 2019-08-22 2022-09-08 Dr. Reddy's Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
EP4541786A3 (en) 2020-09-04 2025-08-06 Synthon B.V. Improved process for preparation of apalutamide
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004753A1 (en) * 2005-05-13 2007-01-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007127010A2 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
EP4385574A3 (en) 2006-03-27 2024-10-02 The Regents of the University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
KR101819199B1 (ko) 2010-02-16 2018-01-16 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제 및 이의 용도
CN113135892A (zh) 2012-06-07 2021-07-20 阿拉贡药品公司 雄激素受体调节剂的晶形
WO2019242439A1 (zh) 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004753A1 (en) * 2005-05-13 2007-01-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007127010A2 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HITOSHI YOSHINO et al.: "Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer", Bioorganic & Medicinal Chemistry, 2010, vol. 18, No. 23, pp. 8150-8157, See the whole document. *
MICHAEL E. JUNG et al.: "Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)", Journal of Medicinal Chemistry, 2010, vol. 53, No. 7, pp. 2779-2796, See the whole document. *

Also Published As

Publication number Publication date
KR102195916B1 (ko) 2020-12-30
US9994545B2 (en) 2018-06-12
DK2858985T3 (en) 2018-05-28
ES2875932T3 (es) 2021-11-11
CA3008345C (en) 2019-10-22
NZ717683A (en) 2018-04-27
PL3533792T3 (pl) 2021-11-29
US20210163441A1 (en) 2021-06-03
TW201402561A (zh) 2014-01-16
CR20190331A (es) 2019-11-12
PH12016501470A1 (en) 2017-07-10
SG10201610248SA (en) 2017-02-27
KR20150021993A (ko) 2015-03-03
EA201791592A1 (ru) 2018-01-31
HUE038082T2 (hu) 2018-09-28
MY187500A (en) 2021-09-24
SMT201800311T1 (it) 2018-07-17
JP6182209B2 (ja) 2017-08-16
ZA201500076B (en) 2016-10-26
IL267608B1 (en) 2025-06-01
GT201400283A (es) 2017-07-03
SI3533792T1 (sl) 2021-11-30
US20180258067A1 (en) 2018-09-13
AU2013271751B2 (en) 2017-02-23
LT2858985T (lt) 2018-09-25
NL301144I2 (nl) 2025-03-20
LTC3533792I2 (enExample) 2024-07-10
US10308630B2 (en) 2019-06-04
RS61988B1 (sr) 2021-07-30
ES2809738T3 (es) 2021-03-05
IN2014DN10084A (enExample) 2015-08-21
HRP20180902T1 (hr) 2018-08-24
EP3533792A1 (en) 2019-09-04
IL320522A (en) 2025-06-01
DK3348553T3 (da) 2020-07-27
NZ702203A (en) 2016-09-30
CY1123427T1 (el) 2021-12-31
CN113135892A (zh) 2021-07-20
RS57370B1 (sr) 2018-08-31
HRP20210909T1 (hr) 2021-09-03
US20200354335A1 (en) 2020-11-12
AU2017200298A1 (en) 2017-02-02
RS60617B1 (sr) 2020-09-30
EP2858985B1 (en) 2018-04-18
CY2021032I1 (enExample) 2022-03-24
JP2015518890A (ja) 2015-07-06
SI2858985T1 (sl) 2018-12-31
SI3348553T1 (sl) 2020-11-30
PL2858985T3 (pl) 2018-09-28
US20200115361A1 (en) 2020-04-16
WO2013184681A1 (en) 2013-12-12
MX356754B (es) 2018-06-11
US12018008B2 (en) 2024-06-25
PH12014502714B1 (en) 2015-02-02
US10556882B2 (en) 2020-02-11
PT3348553T (pt) 2020-09-28
UA123142C2 (uk) 2021-02-24
CO7240407A2 (es) 2015-04-17
CA3055660A1 (en) 2013-12-12
PH12016501470B1 (en) 2021-12-10
CN105693692A (zh) 2016-06-22
SG10201610249TA (en) 2017-02-27
JP6345821B2 (ja) 2018-06-20
LUC00236I2 (enExample) 2025-02-03
US20250092011A1 (en) 2025-03-20
EA028791B1 (ru) 2017-12-29
BR112014030678A2 (pt) 2017-06-27
LT3348553T (lt) 2020-09-25
PE20200725A1 (es) 2020-07-21
ME03815B (me) 2021-04-20
CY1120393T1 (el) 2019-07-10
HK1226066A1 (zh) 2017-09-22
EA201492272A1 (ru) 2015-05-29
ECSP14030098A (es) 2016-01-29
AU2017279807A1 (en) 2018-01-25
FR21C1050I1 (fr) 2021-12-10
EP3348553A1 (en) 2018-07-18
HK1210175A1 (en) 2016-04-15
CL2014003331A1 (es) 2016-03-04
MX2014015005A (es) 2015-09-04
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
IL236055A0 (en) 2015-02-01
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
IL259738A (en) 2018-07-31
CY1124831T1 (el) 2022-03-24
EA201992010A1 (ru) 2020-01-24
EP2858985A4 (en) 2016-05-25
PE20200795A1 (es) 2020-08-10
LT3533792T (lt) 2021-07-26
US20190241539A1 (en) 2019-08-08
CA2875767C (en) 2018-08-14
PT2858985T (pt) 2018-07-10
CR20140549A (es) 2015-04-06
AU2013271751A1 (en) 2014-12-18
US10766875B2 (en) 2020-09-08
IL275413A (en) 2020-07-30
IL259738B (en) 2021-06-30
SMT202100355T1 (it) 2021-07-12
US10526310B2 (en) 2020-01-07
KR20190132543A (ko) 2019-11-27
PL3348553T3 (pl) 2021-02-08
IL267608B2 (en) 2025-10-01
HUE054595T2 (hu) 2021-09-28
UA115665C2 (uk) 2017-12-11
AU2017279807B2 (en) 2018-11-08
EP3348553B1 (en) 2020-07-08
EP3533792B1 (en) 2021-05-05
LTPA2021525I1 (enExample) 2021-11-25
CA2875767A1 (en) 2013-12-12
EP2858985A1 (en) 2015-04-15
US9481663B2 (en) 2016-11-01
HRP20201387T1 (hr) 2020-11-27
ME03081B (me) 2019-01-20
DK3533792T3 (da) 2021-06-28
AU2017200298B2 (en) 2017-09-28
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
NO2021046I1 (no) 2021-11-02
SG11201408140QA (en) 2015-01-29
FR21C1050I2 (fr) 2024-05-24
EP3922629A1 (en) 2021-12-15
US20170001977A1 (en) 2017-01-05
TR201808939T4 (tr) 2018-07-23
JP2018141009A (ja) 2018-09-13
CN104619692A (zh) 2015-05-13
CY2021032I2 (el) 2022-03-24
IL267608A (en) 2019-08-29
JP2017178923A (ja) 2017-10-05
PH12014502714A1 (en) 2015-02-02
PE20150631A1 (es) 2015-05-11
TWI532732B (zh) 2016-05-11
PT3533792T (pt) 2021-06-07
US20150133481A1 (en) 2015-05-14
CA3008345A1 (en) 2013-12-12
CA3114726A1 (en) 2013-12-12
US20190330182A1 (en) 2019-10-31
HUS2100047I1 (hu) 2021-11-29

Similar Documents

Publication Publication Date Title
EA033956B1 (ru) Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7- диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты
HK40068033A (en) Crystalline forms of an androgen receptor modulator
HK40056921A (en) Crystalline forms of an androgen receptor modulator